Should the Denosumab Metastasis Prevention Trial Change Practice for Men with Nonmetastatic Prostate Cancer?

Autor Saylor, Philip J., Michaelson, M. Dror
Vydáno 2012

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?

Autor Gao, Xin, McDermott, David F., Michaelson, M. Dror
Vydáno v Oncologist (2019)

Prostate cancer (metastatic)

Autor Michaelson, M Dror, Smith, Matthew R R, Talcott, James A A
Vydáno 2003

Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate Cancer

Autor Saylor, Philip J., Kaufman, Donald S., Michaelson, M. Dror, Lee, Richard J., Smith, Matthew R.
Vydáno 2010

Treatment sequences for advanced renal cell carcinoma: A health economic assessment

Autor Deniz, Baris, Ambavane, Apoorva, Yang, Shuo, Altincatal, Arman, Doan, Justin, Rao, Sumati, Michaelson, M. Dror
Vydáno v PLoS One (2019)

Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metast...

Autor Saylor, Philip J., Mahmood, Umar, Kunawudhi, Anchisa, Smith, Matthew R., Palmer, Edwin L., Michaelson, M. Dror
Vydáno 2012

Application of dynamic modeling for survival estimation in advanced renal cell carcinoma

Autor Deniz, Baris, Altincatal, Arman, Ambavane, Apoorva, Rao, Sumati, Doan, Justin, Malcolm, Bill, Michaelson, M. Dror, Yang, Shuo
Vydáno v PLoS One (2018)

Management of Complications of Prostate Cancer Treatment

Autor Michaelson, M. Dror, Cotter, Shane E., Gargollo, Patricio C., Zietman, Anthony L., Dahl, Douglas M., Smith, Matthew R.
Vydáno 2008

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)

Autor Molina, Ana M., Hutson, Thomas E., Larkin, James, Gold, Anne M., Wood, Karen, Carter, Dave, Motzer, Robert, Michaelson, M. Dror
Vydáno 2013

Quality of Life Predicts Progression-Free Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Versus Interferon Alfa

Autor Cella, David, Cappelleri, Joseph C., Bushmakin, Andrew, Charbonneau, Claudie, Li, Jim Z., Kim, Sindy T., Chen, Isan, Michaelson, M. Dror, Motzer, Robert J.
Vydáno 2009

Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer

Autor Michaelson, M. Dror, Kaufman, Donald S., Lee, Hang, McGovern, Francis J., Kantoff, Philip W., Fallon, Mary Anne, Finkelstein, Joel S., Smith, Matthew R.
Vydáno 2007

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

Autor DePrimo, Samuel E, Bello, Carlo L, Smeraglia, John, Baum, Charles M, Spinella, Dominic, Rini, Brian I, Michaelson, M Dror, Motzer, Robert J
Vydáno 2007

Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials

Autor Tannir, Nizar M., Figlin, Robert A., Gore, Martin E., Michaelson, M. Dror, Motzer, Robert J., Porta, Camillo, Rini, Brian I., Hoang, Caroline, Lin, Xun, Escudier, Bernard
Vydáno v Clin Genitourin Cancer (2017)

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

Autor Donskov, Frede, Michaelson, M Dror, Puzanov, Igor, Davis, Mellar P, Bjarnason, Georg A, Motzer, Robert J, Goldstein, David, Lin, Xun, Cohen, Darrel P, Wiltshire, Robin, Rini, Brian I
Vydáno v Br J Cancer (2015)

Radium-223 dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases

Autor McKay, Rana R., Bossé, Dominick, Gray, Kathryn P., Michaelson, M. Dror, Krajewski, Katherine, Jacene, Heather A., Walsh, Meghara, Bellmunt, Joaquim, Pomerantz, Mark, Harshman, Lauren C., Choueiri, Toni K.
Vydáno v Clin Cancer Res (2018)

Two Phase II Trials of the Novel Akt Inhibitor Perifosine in Patients with Advanced Renal Cell Carcinoma Following Progression on VEGF-Targeted Therapy

Autor Cho, Daniel C., Hutson, Thomas E., Samlowski, Wolfram, Sportelli, Peter, Somer, Brad, Richards, Paul, Sosman, Jeffrey A., Puzanov, Igor, Michaelson, M. Dror, Flaherty, Keith T., Figlin, Robert A, Vogelzang, Nicholas J
Vydáno 2012

Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma

Autor Cella, David, Davis, Mellar P, Négrier, Sylvie, Figlin, Robert A, Michaelson, M Dror, Bushmakin, Andrew G, Cappelleri, Joseph C, Sandin, Rickard, Korytowsky, Beata, Charbonneau, Claudie, Matczak, Ewa, Motzer, Robert J
Vydáno v Cancer (2014)

NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy

Autor Hudes, Gary R., Carducci, Michael A., Choueiri, Toni K., Esper, Peg, Jonasch, Eric, Kumar, Rashmi, Margolin, Kim A., Michaelson, M. Dror, Motzer, Robert J., Pili, Roberto, Roethke, Susan, Srinivas, Sandy
Vydáno v J Natl Compr Canc Netw (2011)

A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystecto...

Autor Michaelson, M. Dror, Hu, Chen, Pham, Huong T., Dahl, Douglas M., Lee-Wu, Chin, Swanson, Gregory P., Vuky, Jacqueline, Lee, R. Jeffrey, Souhami, Luis, Chang, Brian, George, Asha, Sandler, Howard, Shipley, William
Vydáno v Int J Radiat Oncol Biol Phys (2016)

A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases

Autor Lee, Richard J., Saylor, Philip J., Michaelson, M. Dror, Rothenberg, S. Michael, Smas, Malgorzata E., Miyamoto, David T., Gurski, Carol A., Xie, Wanling, Maheswaran, Shyamala, Haber, Daniel A., Goldin, Jonathan G., Smith, Matthew R.
Vydáno 2013